泰坦科技完成ASL100%股权交割，加速海外布局

Core Viewpoint - Titan Technology has successfully completed the acquisition of ASL, marking a significant step in its overseas expansion strategy and enhancing its operational capabilities in the chemical industry [1][3]. Group 1: Acquisition Details - The acquisition of 100% equity in ASL has been finalized, with all necessary foreign investment filings and approvals obtained, including certificates from the Shanghai Municipal Commission of Commerce and the Shanghai Development and Reform Commission [1]. - The total acquisition cost was £5.7564 million (approximately RMB 55.85 million), which has been fully paid to the seller, Central Glass Japan [1]. - ASL will be integrated into Titan Technology's consolidated financial statements as a wholly-owned subsidiary [1]. Group 2: ASL's Business Overview - ASL specializes in the distribution and customized services of chemical products, serving a diverse clientele that includes global pharmaceutical companies, biotechnology firms, academic research institutions, and chemical enterprises [2]. - The company offers over 100,000 types of compounds, including intermediates, fluorides, and life science reagents, ensuring a wide range of solutions for its customers [2]. - ASL has its own laboratories to maintain product quality and supply chain reliability, and it operates inventory locations in both the UK and the US [2]. Group 3: Strategic Implications - The acquisition aligns with Titan Technology's strategic development goals, promising enhancements in innovation, overseas production, and operational capabilities [3]. - Post-acquisition, the company plans to integrate ASL into its global supply chain, production technology, product development, and business teams, which is expected to strengthen profitability over time [2][3]. - ASL's business has faced cyclical downturns, with losses reported in 2023 and 2024, but a reduction in losses is anticipated for 2025 following the integration [2].